

Luigi Scotto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7875981/publications.pdf>

Version: 2024-02-01

34
papers

928
citations

840776

11
h-index

501196

28
g-index

35
all docs

35
docs citations

35
times ranked

1716
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: Potential role in progression. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 755-765.	2.8	278
2	Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. <i>Molecular Cancer</i> , 2008, 7, 58.	19.2	103
3	Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study. <i>Blood</i> , 2021, 137, 2161-2170.	1.4	88
4	Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4663-4675.	7.0	80
5	Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in <i>in vitro</i> and <i>in vivo</i> Models of T-Cell Lymphoid Malignancies. <i>Clinical Cancer Research</i> , 2010, 16, 3648-3658.	7.0	70
6	Protocadherin PCDH10, involved in tumor progression, is a frequent and early target of promoter hypermethylation in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 983-992.	2.8	61
7	The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 215-226.	2.5	51
8	Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 2096-2106.	7.0	48
9	Aurora A Kinase Inhibition Selectively Synergizes with Histone Deacetylase Inhibitor through Cytokinesis Failure in T-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 4097-4109.	7.0	41
10	Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. <i>Clinical Cancer Research</i> , 2017, 23, 3084-3096.	7.0	23
11	Epigenetic inactivation of TRAIL decoy receptors at 8p12-21.3 commonly deleted region confers sensitivity to APO2L/trail- α combination therapy in cervical cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 177-189.	2.8	18
12	Development and Characterization of a Novel CD19CherryLuciferase (CD19CL) Transgenic Mouse for the Preclinical Study of B-Cell Lymphomas. <i>Clinical Cancer Research</i> , 2012, 18, 3803-3811.	7.0	9
13	The Investigational Aurora A Kinase Inhibitor Alisertib Exhibits Broad Activity in Preclinical Models of T-Cell Lymphoma and Is Highly Synergistic with Romidepsin. <i>Blood</i> , 2014, 124, 4493-4493.	1.4	8
14	The anti-tumor activity of pralatrexate (PDX) correlates with the expression of RFC and DHFR mRNA in preclinical models of multiple myeloma. <i>Oncotarget</i> , 2020, 11, 1576-1589.	1.8	8
15	IL-22-Independent Protection from Colitis in the Absence of Nkx2.3 Transcription Factor in Mice. <i>Journal of Immunology</i> , 2019, 202, 1833-1844.	0.8	7
16	Targeting the T-Cell Lymphoma Epigenome Induces Cell Death, Cancer Testes Antigens, Immune-Modulatory Signaling Pathways. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1422-1430.	4.1	6
17	ATM inhibition overcomes resistance to histone deacetylase inhibitor due to p21 induction and cell cycle arrest. <i>Oncotarget</i> , 2020, 11, 3432-3442.	1.8	5
18	The Combination Of Hypomethylating Agents and Histone Deacetylase Inhibitors(HDACi) Are Synergistically Cytotoxic and Reverse The Malignant Phenotype In Preclinical Models Of T-Cell Lymphoma. <i>Blood</i> , 2013, 122, 646-646.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Generation of pralatrexate resistant T-cell lymphoma lines reveals two patterns of acquired drug resistance that is overcome with epigenetic modifiers. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 639-651.	2.8	3
20	Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance. <i>BMC Cancer</i> , 2021, 21, 879.	2.6	3
21	The Aurora A Kinase Inhibitor, Alisertib, Has Broad Activity In Nonclinical Models Of T-Cell Lymphoma and Is Highly Synergistic With Romidepsin, But Not With Pralatrexate Or The Proteasome Inhibitor, Ixazomib. <i>Blood</i> , 2013, 122, 5141-5141.	1.4	3
22	Targeting Epigenetic Operations with HDAC Inhibitor and Hypomethylating Drugs in Combination Exhibit Synergy in Preclinical and Clinical Experiences in Drug Resistant T-Cell Lymphoma (TCL): A Translational Focus on Doublet Development. <i>Blood</i> , 2015, 126, 1282-1282.	1.4	3
23	Dual Targeting With The Selective Histone Deacetylase (HDAC) 6 Inhibitor, ACY-1215, and Bortezomib (BOR) Leads To Marked Disruption Of Protein Degradation Pathways and Apoptosis In Preclinical Models Of Lymphoma. <i>Blood</i> , 2013, 122, 648-648.	1.4	3
24	Cancer testis antigen expression across T-cell lymphoma subtypes. <i>Hematological Oncology</i> , 2020, 38, 827-830.	1.7	1
25	Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate. <i>Blood</i> , 2012, 120, 2758-2758.	1.4	1
26	The HDACi Romidepsin Markedly Synergizes With Inhibition Of ATM By KU60019 In Mantle Cell Lymphoma. <i>Blood</i> , 2013, 122, 3066-3066.	1.4	1
27	Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies. <i>Blood</i> , 2016, 128, 291-291.	1.4	1
28	N-quinoline-benzenesulfonamide derivatives exert potent anti-lymphoma effect by targeting NF- κ B. <i>IScience</i> , 2020, 23, 101884.	4.1	1
29	Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease. <i>Blood</i> , 2012, 120, 2725-2725.	1.4	0
30	Pre-Clinical Analysis Of The Novel Antifolate Pralatrexate In Multiple Myeloma Reveals Functional Biomarkers Correlated With Response. <i>Blood</i> , 2013, 122, 4430-4430.	1.4	0
31	Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-Kappab in Models of B- and T-Cell Lymphoma. <i>Blood</i> , 2014, 124, 1770-1770.	1.4	0
32	Mechanisms of Acquired Drug Resistance to the Isoform Selective HDAC6 Inhibitor Ricolinostat Reveals Markedly Upregulated Elements of the BTK Pathway Revealing Rational Drug : Drug Combinations. <i>Blood</i> , 2015, 126, 3708-3708.	1.4	0
33	Azacitidine and Romidepsin Synergize to Induce Expression of Cancer Testes Antigens (CTA) and Shift Peripheral T-Cell Lymphoma (PTCL) Cell Lines Toward a Th1-like Phenotype. <i>Blood</i> , 2018, 132, 2845-2845.	1.4	0
34	Inhibition of Casein Kinase 1 Delta Disrupts Translation Initiation and Exerts Potent Anti-Lymphoma Activity. <i>Blood Advances</i> , 0, , .	5.2	0